Octapharma

Founded in 1991, Octapharma France operates a production site in Lingolsheim, near Strasbourg. The company develops and manufactures protein-based medicines derived from human plasma and cell lines. Its products treat bleeding disorders, immune deficiencies, and critical care conditions such as shock and blood volume loss. The production process includes plasma fractionation, purification, and viral inactivation. Octapharma employs over 250 people at its Lingolsheim facility and reported revenue of several billion euros in 2025. The company follows GMP standards and traces each plasma donation through its quality system.